Novel therapy techniques are under investigation, encompassing dual-blockade methodologies and combinations with other drugs such as CDK4/6 inhibitors and immune checkpoint inhibitors, to enhance outcomes for patients with HER2-positive breast cancer[89,90]. The gene discussed is ERBB2; the disease is breast carcinoma.